SLN

Silence Therapeutics PLC

SLN, USA

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

https://www.silence-therapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SLN
stock
SLN

Frazier Life Sciences Management L.P. Decreases Holdings in Silence Therapeutics PLC Sponsored ADR $SLN MarketBeat

Read more →
SLN
stock
SLN

(SLN) Movement as an Input in Quant Signal Sets news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$33.8

Analyst Picks

Strong Buy

3

Buy

3

Hold

0

Sell

1

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.34

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-28.30 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-14.28 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-6,851.57 %

Low 5%

High 15%

Debt to Equity

-

Very Low

0.98

Low 1

High 0.3

Investors

* Institutions hold a combined 38.99% of the total shares of Silence Therapeutics PLC

1.

TCG Crossover Management, LLC

(6.4229%)

since

2025/06/30

2.

Siren, L.L.C.

(6.1643%)

since

2025/06/30

3.

Redmile Group, LLC

(4.5835%)

since

2025/06/30

4.

Lombard Odier Asset Management USA Corp

(3.9164%)

since

2025/06/30

5.

Morgan Stanley - Brokerage Accounts

(2.5656%)

since

2025/06/30

6.

Vivo Capital, LLC

(2.3406%)

since

2025/06/30

7.

Nantahala Capital Management, LLC

(2.2071%)

since

2025/06/30

8.

Nextech Invest, Ltd.

(2.0165%)

since

2025/06/30

9.

Ikarian Capital, LLC

(1.8496%)

since

2025/06/30

10.

5AM Venture Management, LLC

(1.0083%)

since

2025/06/30

11.

International Biotechnology Ord

(0.9401%)

since

2025/07/31

12.

SG Americas Securities, LLC

(0.6528%)

since

2025/06/30

13.

BOOTHBAY FUND MANAGEMENT, LLC

(0.5344%)

since

2025/06/30

14.

UBS Group AG

(0.4838%)

since

2025/06/30

15.

Millennium Management LLC

(0.4206%)

since

2025/06/30

16.

M28 Capital Management LP

(0.3919%)

since

2025/06/30

17.

Marshall Wace Asset Management Ltd

(0.3724%)

since

2025/06/30

18.

HSBC Holdings PLC

(0.3659%)

since

2025/06/30

19.

BlackRock Inc

(0.3562%)

since

2025/06/30

20.

Bank of Montreal

(0.3087%)

since

2025/06/30

21.

BMO Capital Markets Corp.

(0.3087%)

since

2025/06/30

22.

iShares Biotechnology ETF

(0.2974%)

since

2025/08/31

23.

Galileo - Biotech Innovation Fund S USD

(0.1242%)

since

2025/02/28

24.

RIM Global Bioscience EUR

(0.1225%)

since

2025/05/31

25.

Fidelity Nasdaq Composite Index

(0.0625%)

since

2025/07/31

26.

iShares Nasdaq US Biotech ETF USD Acc

(0.0617%)

since

2025/08/31

27.

Virtus LifeSci Biotech Clinical Trls ETF

(0.0465%)

since

2025/08/29

29.

SPDR® S&P® International Small Cap ETF

(0.0168%)

since

2025/08/29

30.

Steward Values Enhanced International I

(0.0123%)

since

2025/07/31

31.

Invesco Nasdaq Biotechnology ETF

(0.0036%)

since

2025/08/29

32.

ProShares Ultra Nasdaq Biotechnology

(0.0035%)

since

2025/08/29

33.

Blackstone Alternative Multi-Strategy I

(0.003%)

since

2024/12/31

34.

GF NASDAQ Bio-Tech Idx QDII USD A

(0.0025%)

since

2025/06/30

35.

CREF Stock R3

(0.0001%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1967

Latest Release

Date

2025-09-30

EPS Actual

-0.15

EPS Estimate

-0.21

EPS Difference

0.06

Surprise Percent

28.5714%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.